Table 2

Comparison of baseline clinical, demographic, endoscopic and laboratory characteristics between patients who received FMT-AID versus those who received optimised SMT

FMT-AID (n=35)SMT (n=31)P value
Age (years), mean±SD33.9±11.337.8±10.70.15
Gender (male), n (%)20 (57.1)20 (64.5)0.54
Disease duration (months), median (IQR)48 (24–96)36 (30–84)0.67
Extent (pancolitis), n (%)13 (37.1)10 (32.3)0.68
Disease severity, n (%)
 Mild
 Moderate
21 (60)
14 (40)
23 (74.2)
8 (25.8)
0.22
Concomitant treatment, n (%)
 5-ASA oral
 5-ASA topical
 Steroid oral
 Topical steroid
 Azathioprine
 Previous biologic
 Past immunomodulator
35 (100)
32 (91.4)
3 (8.6)
26 (74.3)
13 (37.1)
1 (2.9)
21 (60)
31 (100)
30 (96.8)
2 (6.5)
25 (80.6)
9 (29)
1 (3.2)
13 (41.9)
0.69
1
0.54
0.48
1
0.14
Past steroid use, n (%)
 Never
 Steroid within first year
 Steroid <2/year
 Steroid dependent
 Past acute severe ulcerative colitis
5 (14.3)
20 (57.1)
17 (48.6)
13 (37.1)
5 (14.3)
5 (16.1)
17 (54.8)
18 (58.1)
8 (25.8)
6 (19.4)
1
0.85
0.44
0.32
0.58
Median (IQR) SCCAI6 (5–7)6 (5–7)0.37
Median (IQR) UCEIS4 (3–4)3 (3–5)0.79
Haemoglobin (gm/dL), median (IQR)11.8 (10–12.8)11.7 (9.5–14.2)0.64
Platelet count (109/L), median (IQR)290 (206–360)271 (228–327)0.67
Albumin (gm/dL), median (IQR)4.4 (4–4.6)4.5 (4.4–5)0.01
C-reactive protein (mg/L), median (IQR)3.3 (1.1–8.2)1.03 (0.4–4.8)0.1
Faecal calprotectin, µg/g385.2 (292–514)424.6 (237–551)0.99
  • Mild disease: SCCAI 3–6, moderate: SCCAI 7–9.

  • 5-ASA, 5-aminosalicylic acid; FMT-AID, faecal microbiota transplantation and anti-inflammatory diet; SCCAI, Simple Clinical Colitis Activity Index; SMT, standard medical therapy; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.